For the Inventor, By the Inventor

Enter assignee name

Toronto, Canada

Apotex Inc.

USPTO Granted Patents = 67

% Expired Patents = 26.9

EPO Patents = 4

Trademarks = 14

Forward Citations = 237

Loading Chart...

Loading Chart...

103 inventors (with patents filed for the assignee):

Fabio E S Souza (21 out of 30 patents)

Allan W Rey (16 out of 30 patents)

Tim Fat Tam (16 out of 33 patents)

4. Khashayar Karimian (12 out of 16 patents)

5. Avedis Karadeolian (11 out of 11 patents)

6. Wanren Li (11 out of 12 patents)

7. Bahareh Khalili (10 out of 11 patents)

8. Alexander J Stirk (8 out of 8 patents)

9. Annyt Bhattacharyya (7 out of 7 patents)

10. Yajun Zhao (7 out of 19 patents)

11. Gamini Weeratunga (7 out of 33 patents)

12. Prabhudas Bodhuri (7 out of 12 patents)

13. Boris Gorin (6 out of 32 patents)

14. Stuart P Green (6 out of 6 patents)

15. Regis C Leung-Toung (6 out of 19 patents)

Core Competencies:

Crystalline Forms

Active Pharmaceutical Ingredients

Extended Release

Cabozantinib

Oxcarbazepine

Zyclomiphene

Acalabrutinib

Niraparib

Remdesivir

Salts

Formulation Stability

Manufacturing Processes

67 patents: Sort by Forward Citations

1. 12758538 - Crystalline forms of apalutamide (2026-10-13),

2. 12583860 - Processes for the preparation of multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour (2026-03-24),

3. 11980622 - Oxcarbazepine extended release dosage form (2024-05-14),

4. 11814356 - Salt of cabozantinib (2023-11-14),

5. 11667656 - Crystalline forms of Tenofovir alafenamide (2023-06-06),

6. 11661396 - Crystalline forms of zuclomiphene citrate (2023-05-30),

7. 11578025 - Processes for the preparation of zuclomiphene intermediates (2023-02-14),

8. 11440871 - Zuclomiphene salts and crystalline forms thereof (2022-09-13),

9. 11377456 - Crystalline form of Remdesivir (2022-07-05),

10. 11345706 - Crystalline forms of Acalabrutinib (2022-05-31),

11. 11236066 - Crystalline forms of niraparib tosylate (2022-02-01),

12. 11220500 - Crystalline form of Valbenazine dibesylate (2022-01-11),

13. 11072620 - Crystalline forms of Ponatinib hydrochloride (2021-07-27),

14. 11046638 - Processes for the preparation of zuclomiphene and intermediates thereof (2021-06-29),

15. 10875846 - Processes for the preparation of Tezacaftor and intermediates thereof (2020-12-29),

Company Overview

Apotex Inc., headquartered in Toronto, Canada, is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of a wide range of generic and innovative pharmaceutical formulations. The company focuses on key technological areas such as crystalline forms and active pharmaceutical ingredients, with expertise in extended release formulations. Apotex is known for its work on various therapeutic compounds, including cabozantinib, oxcarbazepine, zyclomiphene, acalabrutinib, and niraparib, contributing significantly to global healthcare solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

67 Patents

#20 in Toronto

#199 in Canada

#11,040 in the World

Toronto, Canada

Apotex Inc.

Forward Citations = 237

103 inventors:

Fabio E S Souza (21 out of 30 patents)

Allan W Rey (16 out of 30 patents)

Tim Fat Tam (16 out of 33 patents)

4. Khashayar Karimian (12 out of 16 patents)

5. Avedis Karadeolian (11 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Apotex Inc.. Retrieved from https://idiyas.com/company/apotex

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…